Century Therapeutics, Inc. logo IPSC - Century Therapeutics, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
0
BUY 7
HOLD 2
SELL 0
STRONG
SELL
0
| PRICE TARGET: $2.00 DETAILS
HIGH: $2.00
LOW: $2.00
MEDIAN: $2.00
CONSENSUS: $2.00
DOWNSIDE: 3.38%
Metric 2025 2024 2023 2022 2021 2020 2019
Revenue
Revenue 109.2 6.6 2.2 5.2 0 0 0
Cost of Revenue 13.1 0 0 0 4.6 1.8 0.2
Gross Profit 96.1 6.6 2.2 5.2 (4.6) (1.8) (0.2)
Operating Expenses
R&D Expenses 95.7 107.2 92.7 97.2 75.6 39.7 14.3
SG&A Expenses 24.0 33.2 34.7 31.9 14.7 7.7 5.5
Other Expenses (8.6) 4.3 21.4 10 0 0 0
Operating Expenses 111.1 144.7 148.8 139.0 90.3 47.4 19.8
Operating Income
Operating Income (15.0) (138.1) (146.5) (133.8) (94.9) (49.2) (20.0)
Interest Expense 0 0 0.5 0 1.3 0.4 0
Interest Income 7.3 13.0 12.7 3.0 0.9 0.7 1.2
Profitability
EBITDA 3.5 (111.5) (121.2) (121.2) (89.9) (51.4) (244.5)
EBIT (9.6) (124.8) (134.3) (129.6) (94.5) (53.2) (244.8)
Income Before Tax (9.6) (124.8) (134.8) (130.8) (95.8) (53.6) (244.8)
Income Tax Expense (0.1) 1.8 1.9 0.1 0.0 0 0
Net Income (9.6) (126.6) (136.7) (130.9) (95.8) (53.6) (244.8)
Per Share Data
EPS (Basic) -0.11 -1.61 -2.30 -2.27 -1.74 -1.00 -4.49
EPS (Diluted) -0.11 -1.61 -2.30 -2.27 -1.74 -1.00 -4.49
Shares Outstanding 86.6 78.6 59.3 57.8 55.0 54.8 54.8
Metric 2025 2024 2023 2022 2021 2020 2019
Current Assets
Cash & Cash Equivalents 61.9 58.4 47.3 84.3 56.4 27.2 44.1
Short-Term Investments 55.3 130.9 125.4 231.2 166.4 48.5 37.5
Net Receivables 0.7 1.5 0.7 0.8 0.2 0.9 0.1
Inventory 0 0 0 0 0 0 0
Other Current Assets 1.7 0.9 1.8 0.5 2.8 1.8 0.3
Total Current Assets 120.8 194.1 177.0 319.7 228.2 78.8 84.1
Non-Current Assets
Property, Plant & Equipment 66.2 90.8 92.1 111.7 69.8 24.8 2.5
Goodwill 0 0 0 0 0 0 0
Intangible Assets 34.2 34.2 0 0 0 9.4 0
Long-Term Investments 2.4 30.8 91.1 51.9 135.9 1.1 4.1
Other Non-Current Assets 0.2 3.3 0.5 3.2 3.5 (7.2) 0.2
Total Non-Current Assets 102.9 159.2 183.7 166.8 209.2 28.0 6.8
Total Assets 223.7 353.2 360.7 486.5 437.4 106.8 90.9
Current Liabilities
Account Payables 4.8 3.1 2.7 5.5 7.6 8.1 1.5
Short-Term Debt 0 0 1.5 6.5 1.0 0 0
Deferred Revenue 0 109.2 4.4 7.2 0 0 0
Other Current Liabilities 3.8 0.1 2.7 3.2 1.1 0.1 0.1
Total Current Liabilities 20.2 129.8 17.8 29.8 15.7 12.1 3.0
Non-Current Liabilities
Long-Term Debt 0 0 0 3.7 8.9 9.6 0
Deferred Tax Liabilities 4.3 4.4 0 0 0 0 0
Other Non-Current Liabilities 0 8.7 0.1 0.7 2.0 179.8 179.8
Total Non-Current Liabilities 44.5 62.1 158.1 154.0 25.5 201.1 179.8
Total Liabilities 64.8 191.9 175.9 183.8 41.1 213.2 182.8
Stockholders' Equity
Common Stock 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Retained Earnings (791.9) (782.3) (655.8) (519.1) (388.2) (292.3) (238.8)
Accumulated Other Comprehensive Income 0.0 0.3 0.1 (2.5) (0.7) (0.0) (0.0)
Total Stockholders' Equity 158.9 161.4 184.8 302.7 396.2 (106.4) (91.9)
Total Liabilities & Equity 223.7 353.2 360.7 486.5 437.4 106.8 90.9
Debt Metrics
Total Debt 43.6 53.8 48.2 49.4 25.1 21.6 0
Net Debt (18.3) (4.6) 0.8 (34.9) (31.3) (5.7) (44.1)
Metric 2025 2024 2023 2022 2021 2020 2019
Operating Activities
Net Income (9.6) (126.6) (136.7) (130.9) (95.8) (53.6) (244.8)
Depreciation & Amortization 13.1 13.3 13.0 8.4 3.7 1.4 0.2
Stock-Based Compensation 6.8 12.7 14.6 10.7 4.7 0.9 0.1
Change in Working Capital (114.6) (9.3) 9.4 123.9 (2.8) 4.9 2.3
Other Non-Cash Items 0.4 (1.2) 11.3 1.9 1.2 5.2 225.9
Operating Cash Flow (103.9) (110.1) (88.3) 14.1 (89.0) (41.3) (16.2)
Investing Activities
Capital Expenditure (0.8) (0.2) (13.7) (30.6) (45.0) (9.8) (2.5)
Acquisitions 0 (9.6) 0 (238.2) 0 0 0
Purchases of Investments (51.2) (119.5) (209.0) (254) (330.0) (49.9) (41.5)
Sales/Maturities of Investments (51.2) 176.8 283.9 271.5 76.7 41.6 0
Other Investing Activities 210.7 0 0 238.2 0 (4.7) 24.2
Investing Cash Flow 107.5 47.5 61.1 (13.1) (298.3) (22.8) (19.8)
Financing Activities
Net Debt Issuance 0 0 (10.2) 0 0 9.7 0
Stock Repurchased 0 0 0 0 0 0 0
Dividends Paid 0 0 0 0 0 0 0
Other Financing Activities 0 0 0 0 36.5 38.0 0
Financing Cash Flow 0.2 74.6 (9.7) 27.2 417.8 47.7 74.8
Cash Position
Net Change in Cash 3.8 11.9 (36.9) 28.1 30.4 (16.3) 38.8
Cash at Beginning 61.2 49.3 86.2 58.2 27.7 44.1 31.4
Cash at End 65.0 61.2 49.3 86.2 58.2 27.7 70.3
Free Cash Flow (104.7) (110.3) (102.1) (16.6) (134.0) (51.1) (18.6)
Key Metrics 2025 2024 2023 2022 2021 2020 2019
Income Statement
Revenue 109.2 6.6 2.2 5.2 0 0 0
Gross Profit 96.1 6.6 2.2 5.2 (4.6) (1.8) (0.2)
Operating Income (15.0) (138.1) (146.5) (133.8) (94.9) (49.2) (20.0)
Net Income (9.6) (126.6) (136.7) (130.9) (95.8) (53.6) (244.8)
EPS (Diluted) -0.11 -1.61 -2.30 -2.27 -1.74 -1.00 -4.49
Balance Sheet
Cash & Equivalents 61.9 58.4 47.3 84.3 56.4 27.2 44.1
Total Assets 223.7 353.2 360.7 486.5 437.4 106.8 90.9
Total Debt 43.6 53.8 48.2 49.4 25.1 21.6 0
Stockholders' Equity 158.9 161.4 184.8 302.7 396.2 (106.4) (91.9)
Cash Flow
Operating Cash Flow (103.9) (110.1) (88.3) 14.1 (89.0) (41.3) (16.2)
Capital Expenditure (0.8) (0.2) (13.7) (30.6) (45.0) (9.8) (2.5)
Free Cash Flow (104.7) (110.3) (102.1) (16.6) (134.0) (51.1) (18.6)